News &amp; Updates

The increasing prevalence of obesity globally, including in South and Southeast Asia (S-SEA), has become a pressing public health concern, posing significant challenges to local economies, healthcare infrastructures, and individual well-being. [World Obesity Atlas 2022; https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2022_WEB.pdf]

New consensus guideline sets framework for obesity care in South and Southeast Asia

SGLT2 inhibitors help protect renal function in geriatric diabetic kidney disease patients

SGLT2 inhibitors offer similar renal protection for patients with diabetic kidney disease (DKD), even those who are over 75 years of age, according to a study.

SGLT2 inhibitors help protect renal function in geriatric diabetic kidney disease patients

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

03 Jul 2024 by

The combination of avelumab and cisplatin-based chemotherapy as neoadjuvant therapy for MIUC yields high OS and EFS rates at both 1 and 3 years, according to the survival data from the dual-cohort, phase II AURA trial presented at ASCO 2024

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

Vaginal estrogen therapy may be safely used to treat genitourinary symptoms in early-stage breast cancer patients with HR-negative tumours and in those concurrently treated with tamoxifen, according to the results of a target trial emulation. However, its use may be detrimental to disease-free survival (DFS) outcomes in patients receiving aromatase inhibitors.

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

Childhood intake of sweetened drinks tied to adult adiposity

Consumption of sugar-sweetened beverages in early childhood tends to lead to a less healthy dietary pattern and greater adiposity during adulthood, reveals a study.

Childhood intake of sweetened drinks tied to adult adiposity

Rituximab shows promise in management of neuropsychiatric SLE

Treatment with rituximab (RTX) in patients with moderate-to-severe neuropsychiatric (NP) systemic lupus erythematosus (SLE) appears to result in some improvements and to contribute to the use of a much lower steroid dose at 6 months, suggests a study presented at EULAR 2024.

Rituximab shows promise in management of neuropsychiatric SLE

02 Jul 2024

Novel JAK1 inhibitor relieves symptoms in active RA

Use of the selective JAK1 inhibitor SHR0302 significantly improves the clinical signs and symptoms of patients with moderate-to-severe active rheumatoid arthritis (RA) who had shown poor response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to a study presented at EULAR 2024.

Novel JAK1 inhibitor relieves symptoms in active RA

02 Jul 2024

Novel personalized cancer vaccine may delay relapse in HNSCC

TG4050, a novel viral-based personalized cancer vaccine, showed promise in a phase I trial presented during a late-breaking poster presentation at AACR 2024. The investigational vaccine induced polyepitopic immune responses against private neoantigens in resected HPV-negative head and neck squamous cell cancer (HNSCC).

Novel personalized cancer vaccine may delay relapse in HNSCC